PLACID trial proves Plasma therapy for Covid-19 inefficient

Recently, the PLACID Trial, a multicentre randomized controlled trial (RCT), has shown that convalescent plasma (CP) therapy for Covid-19 patients gave no positive effects and did not improve the outcome of the patients.
The trial results indicate that there was no difference in the 28-day mortality.
Progression of Covid-19 from moderate to severe in patients treated with CP along with basic standard care had no difference when compared to basic standard care alone.
The use of CP seemed to improve the resolution of shortness of breath and fatigue in patients with moderate Covid-19.
However, this did not translate into a reduction in 28-day mortality or progression to severe disease.
The ICMR is now considering removing the option of CPT from the national guidelines.
Convalescent Plasma, extracted from the blood of patients recovering from an infection, is a source of antibodies against the infection.
The therapy uses blood from people who have recovered from an illness to help others recover.
PLACID Trial was conducted by the Indian Council of Medical Research (ICMR). It is the first and largest randomized control trial to be completed in the world.